comparemela.com

Latest Breaking News On - Kalbe genexine biologics - Page 1 : comparemela.com

Reviewing I-Mab (NASDAQ:IMAB) and Cerevel Therapeutics (NASDAQ:CERE)

I-Mab (NASDAQ:IMAB – Get Free Report) and Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability. Institutional & Insider Ownership 22.6% of I-Mab shares are […]

United kingdomUnited statesKalbe genexine biologicsAbbvie ireland unlimited companySinopharm group coJumpcan pharmaceutical groupCerevel therapeutics holdings incGet free reportCerevel therapeuticsGiveni mabCerevel therapeuticGenexine biologicsSinopharm groupTherapeutics holdingsI mab dailyI mab

Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

SEOUL, South Korea (BUSINESS WIRE) Oct 23, 2023

Soult ukpyolsiSouth koreaKalbe farmaKalbe genexine biologics kgbioRoche mirceraJongsoo leeSungjune hongKalbe genexine biologicsGenexine incConsumer health divisionPrescription pharmaceuticals divisionIndonesian ministry of foodIndonesia stock exchangeNutritional divisionDistribution logistics divisionGenexine biologics

Henlius Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC

/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of HANSIZHUANG (serplulimab.

United statesUnited kingdomJing huangFosun pharmaWenjie zhangKalbe genexine biologics kgbioJason zhuCancer hospital chinese academy of medical sciencesEuropean commissionBureau of medical administrationEuropean medicines agencyCancer associationDrug administrationPrnewswire shanghai henlius biotech incJournal of the american medical associationJournal of the national cancer center

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐.

United statesSouth koreaKalbe genexine biologicsGivastomig claudinTyler ehlerRaj kannanGigi fengBiopharma hangzhou co ltdBoard of directors the companyEuropean society of medical oncologyCorporate developmentAbbvie incKey clinical programResearch development expensesExchange commissionExchange rate information

Head-To-Head Comparison: I-Mab (NASDAQ:IMAB) versus Xilio Therapeutics (NASDAQ:XLO)

I-Mab (NASDAQ:IMAB – Get Rating) and Xilio Therapeutics (NASDAQ:XLO – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability. Analyst Recommendations This is a breakdown of recent recommendations and […]

United statesKalbe genexine biologicsXilio therapeutics incSinopharm group coAbbvie ireland unlimited companyGet ratingXilio therapeuticsGiveni mabXilio therapeuticSinopharm groupGenexine biologicsI mab daily

vimarsana © 2020. All Rights Reserved.